×
About 3,798 results

ALLMedicine™ Medulloblastoma Center

Research & Reviews  1,456 results

Emerging Epigenetic Therapies for Brain Tumors.
https://doi.org/10.1007/s12017-021-08691-x 10.1177/1533033820960748 10.1371/journal.pone.0080865 10.1038/nature02871 10.1186/s40478-020-00942-5 10.18632/oncotarget.1408 10.1016/j.neuint.2014.06.002 10.1038/s41392-019-0095-0 10.1371/journal.pone.0025114 10.1093/nar/gkv703 10.1002/pmic.201800479 10.3390/cancers8030031 10.1038/nrg3074 10.18632/oncotarget.15206 10.1093/jnen/nlaa059 10.1016/j.semcancer.2008.01.008 10.1186/s40364-019-0174-y 10.1038/s41416-020-0814-x 10.1182/blood-2013-10-533604 10.1016/j.mam.2013.01.005 10.1016/j.canlet.2012.04.008 10.1016/j.gendis.2016.04.007 10.3389/fphar.2017.00495 10.1186/s40478-015-0206-2 10.1038/nn.4190 10.1200/JCO.19.03327 10.1158/1078-0432.CCR-10-0395 10.18632/oncotarget.20741 10.1038/nm.4293 10.15430/JCP.2019.24.2.79 10.1007/s12035-012-8349-7 10.1016/j.semcancer.2009.02.005 10.1038/s41572-019-0063-6 10.3389/fendo.2018.00402 10.1093/neuonc/noz150 10.1186/s40478-014-0180-0 10.1186/s13046-019-1180-5 10.1093/carcin/bgt182 10.1126/science.1236062 10.3389/fonc.2018.00448 10.1128/MCB.00332-09 10.1038/nature13387 10.1007/s10555-009-9188-5 10.1093/neuonc/nos281 10.1371/journal.pone.0024248 10.1001/jama.2017.18718 10.1007/s00401-011-0922-z 10.1038/nature10866 10.18632/oncotarget.362 10.3389/fonc.2012.00205 10.1093/neuonc/nov292 10.22034/APJCP.2018.19.9.2613 10.1093/neuonc/now016 10.4103/2230-973X.167646 10.1093/neuros/nyx262
Neuromolecular Medicine; Kukreja L, Li CJ et. al.

Oct 23rd, 2021 - Malignant brain tumors are among the most intractable cancers, including malignancies such as glioblastoma, diffuse midline glioma, medulloblastoma, and ependymoma. Unfortunately, treatment options for these brain tumors have been inadequate and c...

Regulation of chemosensitivity in human medulloblastoma cells by p53 and the PI3 Kinase...
https://doi.org/10.1158/1541-7786.MCR-21-0277
Molecular Cancer Research : MCR; Naeem A, Harish V et. al.

Oct 13th, 2021 - In medulloblastoma (MB), p53 expression has been associated with chemo- and radiation-resistance and with poor long-term outcomes in the p53-mutated sonic hedgehog, MYC-p53, and p53-positive MB subgroups. We previously established a direct role fo...

Medulloblastoma and esthesioneuroblastoma in a pediatric patient: a co-incidence or res...
https://doi.org/10.1007/s00381-021-05346-x 10.3171/2019.5.PEDS18381 10.1007/s00381-018-3869-8 10.1002/ana.410440305 10.2176/nmc.44.665 10.1007/s00381-006-0062-2 10.1186/s12957-015-0436-6.PMID:25889820;PMCID:PMC4329203 10.1002/pbc.21966 10.1007/s00701-016-3062-3
Child's Nervous System : ChNS : Official Journal of the I... Sahoo SK, Madan R et. al.

Oct 9th, 2021 - Medulloblastoma is the commonest embryonal brain tumor in children. Their association with other neuroepithelial brain tumors is less known. Here we discuss a pediatric patient who developed esthesioneuroblastoma 2 years after treatment of medullo...

Medulloblastoma: novel insights into emerging therapeutic targets.
https://doi.org/10.1080/14728222.2021.1982896
Expert Opinion on Therapeutic Targets; Shaik S, Maegawa S et. al.

Oct 5th, 2021 - Medulloblastoma: novel insights into emerging therapeutic targets.|2021|Shaik S,Maegawa S,Gopalakrishnan V,|

see more →

Guidelines  2 results

SEOM clinical guideline for management of adult medulloblastoma (2020).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057961
Clinical & Translational Oncology : Official Publication ... Luque R, Benavides M et. al.

Apr 2nd, 2021 - Recent advances in molecular profiling, have reclassified medulloblastoma, an undifferentiated tumor of the posterior fossa, in at least four diseases, each one with differences in prognosis, epidemiology and sensibility to different treatments. T...

SIOP PODC adapted treatment recommendations for standard-risk medulloblastoma in low an...
https://doi.org/10.1002/pbc.25313
Pediatric Blood & Cancer; Parkes J, Hendricks M et. al.

Nov 25th, 2014 - Effective treatment of children with medulloblastoma requires a functioning multi-disciplinary team with adequate neurosurgical, neuroradiological, pathological, radiotherapy and chemotherapy facilities and personnel. In addition the treating cent...

see more →

Drugs  10 results see all →

Clinicaltrials.gov  14 results

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
https://clinicaltrials.gov/ct2/show/NCT04743661

Sep 29th, 2021 - Stratum 1: This is a phase 2 single-arm open-label study that will define event-free survival (EFS) and overall survival (OS) following therapy with irinotecan, temozolomide, bevacizumab, and compartmental (intraOmmaya) radioimmunotherapy (cRIT) 1...

Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
https://clinicaltrials.gov/ct2/show/NCT05057702

Sep 27th, 2021 - This is a single arm multi-center pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). Relapsed participants will receive an individualized treatment recommendation including up to four FDA-approved drugs based on the results...

Investigating Safety, Tolerability, Efficacy and PK of Olaparib in Paediatric Patients With Solid Tumours
https://clinicaltrials.gov/ct2/show/NCT04236414

Sep 22nd, 2021 - A Phase I open-label, multicentre study to determine the RP2D of olaparib monotherapy in the paediatric population, and to evaluate the safety, tolerability, PK, PDx and preliminary efficacy of olaparib monotherapy in paediatric patients from ≥6 m...

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
https://clinicaltrials.gov/ct2/show/NCT02095132

Sep 16th, 2021 - PRIMARY OBJECTIVES: I. To estimate the maximum tolerated dose (MTD) and/or recommended phase 2 dose of adavosertib (AZD1755 [MK-1775]) administered on days 1 through 5 every 21 days, in combination with oral irinotecan (irinotecan hydrochloride), ...

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers
https://clinicaltrials.gov/ct2/show/NCT03173950

Sep 5th, 2021 - Background: There are more than 130 identified primary tumors of the central nervous system (CNS). Most have an annual incidence of less than 1000 in the United States. Given the rarity of each of the tumors listed above, there is a paucity of pro...

see more →

News  36 results

Models Pave the Way for Improved Outcomes in Medulloblastoma
https://www.onclive.com/view/models-pave-the-way-for-improved-outcomes-in-medulloblastoma

Oct 6th, 2021 - Robert Wechsler-Reya, PhD The management of medulloblastoma (MB), the most common malignant brain cancer in children, has not changed in decades but breakthroughs are on the horizon. Only 5 years after the definition of the molecular subgroups...

More Children With High-Risk Brain Cancer Now Surviving
https://www.medscape.com/viewarticle/955360

Jul 26th, 2021 - A practice-changing study that used molecular testing to distinguish between subtypes of medulloblastoma has shown a significant improvement in survival for children with high-risk disease who underwent treatment intensification with carboplatin. ...

Adding Carboplatin May Help Some Kids With Medulloblastoma
https://www.medpagetoday.com/hematologyoncology/braincancer/93711

Jul 22nd, 2021 - Intensifying therapy by adding carboplatin was found to be of benefit for one particular subgroup of pediatric high-risk medulloblastoma, findings from a phase III trial showed. Among children and young adults with high-risk medulloblastoma receiv...

BLA Resubmitted to FDA for Pedmark in Prevention of Cisplatin-Induced Ototoxicity in Solid Tumors
https://www.onclive.com/view/bla-resubmitted-to-fda-for-pedmark-in-prevention-of-cisplatin-induced-ototoxicity-in-solid-tumors

Jun 2nd, 2021 - The new drug application seeking the approval of a unique formulation of sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients aged 1 month to less than 18 years of age with localized, nonmeta...

FDA Grants Rare Pediatric Disease Designation to WP1066 for Ependymoma
https://www.onclive.com/view/fda-grants-rare-pediatric-disease-designation-to-wp1066-for-ependymoma

Apr 14th, 2021 - The FDA has granted a rare pediatric disease (RPD) designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.1 The FDA’s recognition of the h...

see more →

Patient Education  1 results see all →